太美医疗科技（02576）发布公告，将在2026年6月23日的年度股东大会上审议授予董事会购回股份的一般授权。根据公司披露，此次授权规模最高可达公司已发行H股总数的10%，即最多可回购约20,042,513股H股。
太美医疗科技指出，回购所需资金将依照中国法律法规、香港上市规则及公司章程的规定，从公司合法可用资源中支出。董事会认为上述购回计划可提升每股价值，符合公司及股东的整体利益。公告同时提及，公司将于2026年6月17日至6月23日暂停办理H股过户，以厘定有资格出席股东大会并表决的股东名单。
公告称，若相关议案获得股东大会通过，董事会在授权有效期内可择机执行购回。该公司强调，回购旨在优化资本结构、增强市场信心，并在保证营运资金充足的前提下进行。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.